Mechanisms of Acquired Resistance to ARV-471, a Novel PROTAC® Estrogen Receptor (ER) Degrader Read More »
Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in ER+ Breast Cancer Models Read More »
The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation Read More »
ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study Read More »
ARV-471, an estrogen receptor (ER) PROTAC® degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2 negative breast cancer: phase 1b cohort (part C) of a phase 1/2 study Read More »
First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer Read More »
The Discovery of ARV-471, an Orally Bioavailable Estrogen Receptor Degrading PROTAC® for the Treatment of Patients with Breast Cancer Read More »
